NCT03245788

Brief Summary

The Stanford Cancer Center is undertaking a Transformation Initiative in order to improve the quality of care and care coordination across the continuum of care. The newest innovation is to introduce lay navigators to specified high-need patients. The larger goal of the project is to assess whether lay navigators can address non-clinical patient needs in a timely fashion and appropriately connect them with their clinical team when warranted. It is expected that proactive interaction with patients will decrease patient anxiety/stress related to their cancer and facilitate higher patient engagement and improved management of physical, social,and emotional health. For the pilot project, the smaller goal is to understand: how lay navigator time is used; the types and frequency of issues brought up by patients; resources that patients are given or referred to; type and frequency of mode of contact with patients; and patients' acceptance of navigators based on refusal. An electronic intake form will be used to collect this information so that data can be analyzed regularly to inform changes to the navigator program as needed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,053

participants targeted

Target at P75+ for not_applicable breast-cancer

Timeline
Completed

Started Feb 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2017

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 4, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 10, 2017

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

April 8, 2019

Status Verified

April 1, 2019

Enrollment Period

1.5 years

First QC Date

May 4, 2017

Last Update Submit

April 5, 2019

Conditions

Keywords

Lay NavigatorQuality of CareHigh-Need Cancer Treatment Regimen

Outcome Measures

Primary Outcomes (2)

  • Patient Experience/Satisfaction: Difference in topbox scores

    Difference in topbox scores from apriori selected questions from the transformation evaluation in navigated vs not navigated patients.

    3-18 months after eligibility is determined

  • Rates of unplanned hospitalization and ER visits

    Comparison of rates of unplanned hospitalizations and ER visits among eligible patients in the navigated group vs. un-navigated patients.

    0-18 months after eligibility is determined

Secondary Outcomes (1)

  • Utilization of non-treatment-related cancer services

    0-18 months after eligibility is determined

Study Arms (2)

Lay Navigation

EXPERIMENTAL

Patients with even MRN.

Other: Lay Navigation

Usual Care

NO INTERVENTION

Patients with odd MRN.

Interventions

Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.

Lay Navigation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • New patient to eligible Cancer Care Program (CCP)
  • Biopsy positive
  • Plan to receive at least one treatment modality at Stanford: surgery, chemotherapy and/or radiation therapy
  • Cancer that is treated by any of the following CCPs: Breast, Gynecologic oncology, Head/neck, Cutaneous (melanoma only), Thoracic, Gastrointestinal
  • Patient has even numbered MRN

You may not qualify if:

  • Anyone with odd numbered MRN
  • Anyone in other cancer programs that are not included
  • Biopsy negative
  • No treatment modality received
  • Patients with already established care/treatment i.e. not new patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford Cancer Center

Palo Alto, California, 94305, United States

Location

Related Publications (4)

  • Hennink MM, Kaiser BN, Marconi VC. Code Saturation Versus Meaning Saturation: How Many Interviews Are Enough? Qual Health Res. 2017 Mar;27(4):591-608. doi: 10.1177/1049732316665344. Epub 2016 Sep 26.

    PMID: 27670770BACKGROUND
  • O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed methods studies. BMJ. 2010 Sep 17;341:c4587. doi: 10.1136/bmj.c4587. No abstract available.

    PMID: 20851841BACKGROUND
  • Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7.

    PMID: 20957426BACKGROUND
  • Winget M, Holdsworth L, Wang S, Veruttipong D, Zionts D, Rosenthal EL, Asch SM. Effectiveness of a Lay Navigation Program in an Academic Cancer Center. JCO Oncol Pract. 2020 Jan;16(1):e75-e83. doi: 10.1200/JOP.19.00337. Epub 2019 Oct 24.

MeSH Terms

Conditions

Breast NeoplasmsHead and Neck NeoplasmsGastrointestinal NeoplasmsSkin NeoplasmsUrologic NeoplasmsLymphomaSarcoma

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesUrogenital NeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrologic DiseasesNeoplasms by Histologic TypeLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesNeoplasms, Connective and Soft Tissue

Study Officials

  • Steve Asch, MD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
No masking occurs.
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: There will be 12 groups in each arm which reflects the 12 different cancer types.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Associate Professor

Study Record Dates

First Submitted

May 4, 2017

First Posted

August 10, 2017

Study Start

February 15, 2017

Primary Completion

July 31, 2018

Study Completion

December 31, 2018

Last Updated

April 8, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Locations